A recent study by Han et al. demonstrated that metformin reversed PARP inhibitor-induced epithelial-mesenchymal transition (EMT) and PD-L1 expression, which sensitized PARP inhibitor-resistant cells to cytotoxic T cells, suggesting that the combination may increase tumor sensitivity to immunotherapy [112]. This evidence concerns the gene CD274 and neoplasm.